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Since the ﬁ  rst approval of biologic therapy for rheumatoid 
arthritis (RA) in 1998, the treatment of the disease has 
changed substantially. A number of diﬀ  erent  biologic 
agents targeting various cytokines are currently available, 
but few data exist comparing the eﬀ  ectiveness of one 
biologic agent with another, highlighting the importance 
and need for comparative eﬀ  ectiveness research (CER) in 
RA [1]. In fact, comparative eﬀ  ectiveness of biologic therapy 
in RA was one of the top 25 priority research topics 
recom  mended by the Institute of Medicine in 2009 [2].
A number of diﬀ  erent study designs such as random-
ized clinical trials, meta-analyses of randomized clinical 
trials, and observational studies using various data 
sources including patient registries, electronic medical 
records, and administrative claims databases can be 
considered for CER. Th   e use of randomized clinical trials 
is limited in CER because of intrinsic weaknesses such as 
lack of generalizability, insuﬃ   cient  sample  size, 
inadequate follow-up time, and high cost. Observational 
study designs include prospective registries and retro-
spective analysis of administrative healthcare data, often 
collected for insurance payment.
Prospective RA patient registries have a number of 
beneﬁ  ts, including detailed information on RA diagnosis, 
disease activity, and treatment, but often have limited 
generalizability and sample size, and incomplete data on 
comorbidities and other medications [3]. Observational 
studies, particularly those using large administrative 
claims databases, have therefore become increasingly 
popular sources of CER or comparative safety research, 
because they have several important strengths such as 
large size and eﬃ   ciency, generalizability, high validity and 
completeness of prescription drug data, and low cost [4]. 
Furthermore, a previous validation study showed that RA 
patients can be accurately identiﬁ  ed using a combination 
of diagnosis codes and disease-modifying antirheumatic 
drug (DMARD) prescriptions in claims data [5]. 
However, pharmacoepidemiologic studies using claims 
data face challenges and criticisms due to the lack of 
certain clinical information, such as lifestyle risk factors, 
disease severity, and questionable accuracy of disease 
diagnoses. A number of previous studies successfully 
used claims data to assess comparative eﬀ  ectiveness of 
DMARDs on speciﬁ  c outcomes [6,7], but not so much 
research has been done to compare the eﬀ  ectiveness of 
DMARDs in RA activity.
In the current issue of Arthritis Research & Th  erapy, 
Curtis and colleagues present the development and 
validation of a novel, claims-based algorithm to evaluate 
the clinical eﬀ   ectiveness of RA medications [1]. Th  is 
study has an important implication in CER of RA and 
shows the potential for using the claims data to compare 
the clinical eﬀ   ectiveness of multiple biologic or non-
biologic DMARDs in large real-world populations. RA 
patients initiating one of the biologic agents (abatacept, 
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© 2011 BioMed Central Ltdadalimumab, etanercept, inﬂ  iximab and rituximab) were 
identiﬁ   ed based on the data from the longitudinal 
Veterans Aﬀ   airs RA registry linked to the Veterans 
Health Administration medical and pharmacy claims [1]. 
Th  e eﬀ   ectiveness algorithm consists of strict, a priori 
deﬁ   ned criteria: high drug adherence, an increase in 
biologic dose compared with the starting dose, switching 
to a diﬀ   erent biologic or adding a new nonbiologic 
DMARD, initiation of chronic glucocorticoids, an 
increase in glucocorticoid dose during the follow-up 
period, and more than one parenteral or intra-articular 
injection on a given day after the patient had been on 
biologic treatment for longer than 3 months. Th  e gold 
standard for eﬀ  ectiveness was deﬁ  ned as 28-joint Disease 
Activity Score <3.2 (low disease activity) or improvement 
in 28-joint Disease Activity Score >1.2 units at the 1-year 
follow-up visit following the index visit. In the authors’ 
preliminary assessment, the algorithm seems promising 
with good performance characteristics, ranging from 75 
to 90% [1].
While this study represents an important eﬀ  ort, several 
potential pitfalls in this claims-based eﬀ  ectiveness 
algorithm should be noted. First, performance of the 
algorithm may be database dependent. In other words, 
the algorithm may perform diﬀ  erently in a commercially 
insured or Medicare population versus the Veterans 
Aﬀ  airs population in which it was developed. Whether 
the algorithm will have a similar performance in other 
claims databases therefore needs to be further examined. 
Second, as the algorithm required patients to have high 
adherence to DMARDs (over 80%), it may not perform 
well in non  adherent patients. One cannot therefore 
assume the algorithm represents good disease control 
since it was developed in a population who were medi  ca-
tion adherent. Th   ird, the performance of the eﬀ  ectiveness 
algorithm was assessed at 1-year follow-up. As the 
authors suggested, the validity of the algorithm should be 
conﬁ  rmed at diﬀ  erent time points.
A claims-based eﬀ  ectiveness algorithm with acceptable 
performance characteristics across diﬀ  erent data settings 
will be a powerful and desired tool for CER of RA. Such 
an algorithm will enable large-scale, population-based 
studies comparing the eﬀ  ectiveness of diﬀ  erent DMARD 
regimens. Such studies will facilitate head-to-head com-
parisons, supplementing typical randomized controlled 
trials and prospective registries that usually include 
disease activity.
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